Granted Patent
B2
US 10,428,023 · App. 16/052,967 · Granted Oct 1, 2019
Heterocyclic compound and use thereof
Inventors:
Yuichi Kajita (Kanagawa, JP); Yuhei Miyanohana (Kanagawa, JP); Tatsuki Koike (Kanagawa, JP); Kohei Takeuchi (Kanagawa, JP); Yoshiteru Ito (Kanagawa, JP); Norihito Tokunaga (Kanagawa, JP); Takahiro Sugimoto (Kanagawa, JP); Tohru Miyazaki (Kanagawa, JP); Tsuneo Oda (Kanagawa, JP); Yasutaka Hoashi (Kanagawa, JP); Yasushi Hattori (Kanagawa, JP); Keisuke Imamura (Kanagawa, JP)
Assignee:
Takeda Pharmaceutical Company Limited
C07D211/56A61P25/00C07D205/04C07D207/14C07D211/36C07D401/06C07D401/10C07D401/14C07D403/06C07D405/06C07D405/10C07D405/12C07D413/06C07D417/06C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
Claims (1)
1. N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3′,5′-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)methanesulfonamide or a salt thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 22, 2019
From: KAJITA, YUICHI; MIKAMI, SATOSHI; MIYANOHANA, YUHEI; KOIKE, TATSUKI; DAINI, MASAKI; OYABU, NORIO; OGINO, MASAKI; TAKEUCHI, KOHEI; ITO, YOSHITERU; TOKUNAGA, NORIHITO; SUGIMOTO, TAKAHIRO; MIYAZAKI, TOHRU; ODA, TSUNEO; HOASHI, YASUTAKA; HATTORI, YASUSHI; IMAMURA, KEISUKE
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 048088/0939 →
Priority Claims (2)
JP 2017-150685
· Aug 3, 2017
· national
JP 2017-248495
· Dec 25, 2017
· national
Continuity (1)